Dataset from A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009942
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of
Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose
schedule, with a single booster vaccination administered in one cohort in healthy adults aged
greater than or equal to (>=) 18 to less than or equal to (<=) 55 years and in adults aged >=
65 years in good health with or without stable underlying conditions. The purpose of the
study is also to assess the safety and reactogenicity of Ad26.COV2.S administered as ad hoc
booster vaccination in healthy adults aged >= 18 to <= 55 years and in adults >= 65 years in
good health with or without stable underlying conditions.
创建时间：
2025-02-10
